Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers
Version of Record online: 7 FEB 2012
© 2012 BJU INTERNATIONAL
Volume 110, Issue 6, pages 840–845, September 2012
How to Cite
Dhani, N. C., Emmenegger, U., Adams, L., Jongstra, J., Tannock, I. F., Sridhar, S. S., Knox, J. J., Day, J. R., Groskopf, J. and Joshua, A. M. (2012), Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. BJU International, 110: 840–845. doi: 10.1111/j.1464-410X.2011.10922.x
- Issue online: 24 AUG 2012
- Version of Record online: 7 FEB 2012
- Accepted for publication 9 November 2011
FIG. S1. Cytarabine Inhibits growth and clonogenicity of prostate cancer cell lines. A, growth inhibition of DU-145, PC3 and 22Rv1 cells by cytarabine using a SRB based assay. Cells were treated in 96-well plates for 72 h with AraC and the results of the SRB assay were expressed as the OD570 as the % of the OD570 relative to untreated control wells. The 50% growth inhibition is indicated with a thin horizontal line. B, Clonogenic activity of cytarabine, doxorubicin and cisplatin on DU-145 cells. Cells were plated in 6-well plates and treated with compound at a concentration corresponding to their respective half maximal inhibitory concentration values for growth inhibition on DU-145 cells as determined in sulforhodamine B assays.
|BJU_10922_sm_figS1.docx||167K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.